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a b s t r a c t
Objective: The antibacterial activity of Casbane Diterpene (CD) was evaluated in vitro against
Streptococcus oralis, S. mutans, S. salivarius, S. sobrinus, S. mitis and S. sanguinis. The viability of
planktonic cells was analysed by susceptibility tests (MIC and MBC) and antibiofilm action
was assayed.
Methods: The minimal inhibitory and bactericidal concentrations (MIC and MBC) of oral
Streptococcus were evaluated through microdilution tests. To assay antibiofilm activity,
biofilms were generated on 96-wells polystyrene plates under the presence of CD and
quantified by a crystal violet technique and colonies forming units counting.
Results: The CD isolated from Croton nepetaefolius showed antimicrobial effect on planktonic
forms and biofilms of oral pathogens, with MIC values of 62.5 mg/mL against Streptococcus
oralis and values between 125 and 500 mg/mL against S. mutans, S. salivarius, S. sobrinus, S.
mitis and S. sanguinis. CD showed an inhibitory effect on S. mutans biofilm formation at
250 mg/mL, and a decrease on viable cell of 94.28% compared to the normal biofilm growth.
Conclusions: The compound CD can be considered as a promising molecule for the treatment
against oral pathogens responsible for dental biofilm.
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Oral diseases are infections caused by a wide range of
microorganisms that colonize the tooth surface at or below
the gingival margin.1,2 This colonization can led to pathologi-
cal states, including dental caries and periodontal diseases
with tooth loss as consequence. These pathologies may also
involve several serious manifestations that significantly
affects the overall health of the infected individual.3* Corresponding author at: Av. Cmte. Mauroce´lio Rocha Ponte, 100, De
fax: +55 88 3611 8000x227.
E-mail address: edson@ufc.br (E.H. Teixeira).
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Open access under the Elsevier OA license.Pioneer bacterial species multiply to form microcolonies,
which are dipped in mucus bacterial extracellular polysac-
charides and salivary proteins adsorbed, resulting in a
confluent film of microorganisms, a biofilm.4 The metabolism
of these pioneer species creates a suitable condition for
colonization by bacteria with higher levels of atmospheric
demands. The subsequent development of oral biofilm
involves co-aggregations between other genus and the
primary colonizers.4 The mechanical removal of the dental


























Fig. 1 – Structure of Casbane Diterpene extracted from the
stalks of Croton nepetaefolius.
a r c h i v e s o f o r a l b i o l o g y 5 7 ( 2 0 1 2 ) 5 5 0 – 5 5 5 551However, the use of chemicals compounds as a complemen-
tary method is also necessary and has demonstrated to be of
great value with respect to decreasing the tooth biofilm.5,6
Natural products are sources of molecules that can be used
as antimicrobial agents, an attempt to overcome drug
resistance to old and new antimicrobials used currently in
clinical therapy.7 This way, trials focusing anti-biofilm sub-
stances are relevant because of its importance as aetiology of
various persistent and chronic diseases.
Croton is a genus included in Euphorbiaceae family which
is widespread in northeastern Brazil. Its use in popular
medicine is related to cancer treatment, constipation, diabe-
tes, digestive problems, dysentery, external wounds, fever,
hypercholesterolemia, hypertension, inflammation, intestinal
worms, malaria, pain, ulcers, and weight-loss.8 Previous
phytochemical studies have shown that plants of this genus
can produce a large number of diterpenoids,9–19 a class of
natural products that exhibit a wide spectrum of important
biological activities,8 which we can highlight the antimicrobial
activity.20–22 Casbane Diterpenes are a class of diterpenoids
isolated from a few species of plants from Euphorbiaceae
family with mainly anticancer and antibacterial activities.23–31
The present study reports, for the first time, the antimi-
crobial and antibiofilm activities of the Casbane Diterpene
named 1,4-dihydroxy-2E,6E,12E-trien-5-one-casbane (CD) iso-
lated from Croton nepetaefolius against oral bacteria.
2. Materials and methods
2.1. Plant materials
Stalks from C. nepetaefolius were collected in May, 2004, in
Caucaia, Ceara´, Brazil. The sample material was identified by
Dr. Edson Paula Nunes at Prisco Bezerra Herbarium, Biology
Department, Federal University of Ceara´, Fortaleza, CE, Brazil,
where the vouchers specimens (No. 33.582) were deposited.
The bark from stalks (5.0 kg) of C. nepetaefolius was
powdered and solubilized with ethanol (10 L  3, at room
temperature). The solvent was removed under reduced
pressure to form an EtOH extract. The EtOH extract (58.2 g)
was fractionated coarsely in a silica gel column, eluted with
hexane (fractions 1–15), hexane/EtOAc 1:1 (fractions 16–25),
EtOAc (fractions 26–40), and EtOH (fractions 41–48), affording a
total of 48 fractions of 100 mL each. The hexane fractions
(22.5 g) were pooled and fractionated in a silica gel column
using hexane (fractions 10–100), hexane/EtOAc 1:1 (fractions
110–160), EtOAc (fractions 170–210) and EtOH (fractions 220–250),
providing 25 fractions of 100 mL each. Fractions 110–160 (14.0 g),
obtained with hexane/EtOAc (1:1), were fractionated coarsely
in a silica gel column eluted with hexane (fraction 100), hexane/
EtOAc 9:1 (fractions 200–500), 8:2 (fractions 600–1500), 7:3 (fractions
1600–3200), EtOAc (fraction 3300), providing 33 fractions of 100 mL
each. Fractions 1000–1300, obtained with hexane/EtOAc (8:2),
yielded a diterpene named 1,4-dihydroxy-2E,6E,12E-trien-5-
one-casbane (CD) (3.0 g, 0.06%) (Fig. 1). The CD was solubilized
in MiLi-Rios water and dimethylsulfoxide (DMSO) which were
diluted in culture medium reaching a maximum concentra-
tion of 1% (v/v). This percentage of DMSO does not show
interference on microbial growth (data not shown).1,4-dihydroxy-2E,6E,12E-trien-5-one-casbane (CD). Green oil
I.R. (KBr, cm1): 3400, 2920, 1660, 1618, 1020, 756. 1H NMR: 0.99
(s, 3H-16), 1.13 (s, 3H-17), 1.23–1.15 (m, H-9), 1.23–1.15 and 0.79–
0.72 (m, 2H-10), 1.50 (dd, J = 10.4 and 8.3 Hz, H-8), 1.56 (s, 3H-18),
1.66 (s, 3H-19), 1.90 (s, 3H-20), 2.27 (m, 2H-14), 2.27–2.03 and
1.71–1.68 (m, 2H-11), 4.09 (dd, J = 9.6 and 6.2 Hz, H-1), 4.66 (dd,
J = 6.3 Hz, H-13), 5.14 (d, J = 9.4 Hz, H-3), 5.24 (d, J = 9.4 Hz, H-4),
6.25 (d, J = 10.4 Hz, H-7). 13C NMR: 10.15 (C-19), 12.08 (C-20),
15.43 (C-18), 16.12 (C-16), 25.36 (C-10), 27.73 (C-15), 28.08 (C-8),
29.25 (C-17), 31.66 (C-14), 35.67 (C-9), 39.85 (C-11), 67.82 (C-4),
77.64 (C-1), 119.72 (C-13), 125.48 (C-3), 134.61 (C-6), 137.39 (C-
12), 144.02 (C-2), 145.11 (C-7), 199.74 (C-5). MS (70 eV, %) m/z 318
([M]+, absent), 300 (2), 282 (2), 150 (14), 135 (30), 121 (22), 107
(44).
2.2. Bacterial strains and growth conditions
The bacterial strains Streptococcus mutans, Streptococcus salivar-
ius, Streptococcus sobrinus, Streptococcus mitis, Streptococcus
sanguinis and Streptococcus oralis were maintained in BHI/
glycerol (20%) (Brain Heart Infusion-Difco#) at 80 8C. For the
experiments 100 mL aliquot from the stock was inoculated in
10 mL of sterile BHI broth and incubated at a 10% CO2
condition at 37 8C for 24 h. After this initial activation, the
culture was renewed in 10 mL of sterile BHI broth with 100 mL
inoculum and grown under the same conditions described
above for 18 h. This renewal was made to obtain a microor-
ganism with better growth and development. For antimicro-
bial activity tests, the cell density was adjusted at a
concentration of 107 CFU/mL.
2.3. Antimicrobial activity assay
Tests of agar disc diffusion were used as trial for CD
antimicrobial action against the bacteria tested. This meth-
odology was developed accordingly with Performance Standards
for Antimicrobial Disc Susceptibility Tests: Approved Standard –
a r c h i v e s o f o r a l b i o l o g y 5 7 ( 2 0 1 2 ) 5 5 0 – 5 5 5552Tenth Edition. CLSI document M02-A10. As standard, amoxicil-
lin and chlorhexidine were used.
Antimicrobial action of CD was determined by microdilu-
tion test in 96-wells polystyrene plates, standardized accord-
ing with guideline Methods for Dilution Antimicrobial Susceptibility
Tests for Bacteria That Grow Aerobically: Approved Standard – Sixth
Edition. CLSI document M7-A6.
Different concentrations of CD were prepared and
tested through serial dilution (31.25–500 mg/mL). As positive
control it was used chlorhexidine at 250 mg/mL. The MIC
(minimal inhibitory concentration) was considered the
lowest concentration of CD that resulted in visible absence
of bacterial growth. To determine the MBC (minimal
bactericidal concentration) 50 mL of bacterial suspension
from the wells corresponding to each concentration tested
were inoculated in 5 mL of sterile BHI broth medium and
incubated for 24 h 37 8C CO2 10%. MBC was considered the
lowest concentration that inhibited completely bacterial
growth at the medium. For statistical analysis the different




Saliva was collected and processed according to the protocol of
Guggenheim and colleagues.32 Briefly, whole unstimulated
saliva was collected for 1 h per day during several days from
volunteers that assigned an informed consent term (Ethical
Committee Approval number 217-CONEP/CNS/MS) at least
1.5 h after eating, drinking, or tooth cleaning. Saliva samples
were collected in sterile 50 mL polypropylene tubes, chilled in
an ice bath or frozen at 20 8C. After 500 mL saliva had been
collected, it was pooled and centrifuged (30 min, 4 8C,
27,000  g); the supernatant was pasteurized (60 8C, 30 min)
and re-centrifuged in sterile tubes. The resulting supernatant
was stored into sterile 50 mL polypropylene tubes at 80 8C.
The efficiency of the process was assessed by plating
processed saliva samples onto BHI agar; after 72 h at 37 8C
no CFUs were observed on incubated plates.
2.4.2. Biofilm assay
Streptococcus mutans biofilms were grown on 96-wells microtiter
plates through a methodology developed by Stepanovicet al.33
and Islam et al.34 with some modifications. In a first moment,
100 mL of processed saliva plus 100 mL of carbonate buffer pH
9.3 were added to each well and incubated at 4 8C for 2 h. After
this period the wells were washed tree times with saline
phosphate buffer pH 7.6. In sequence, 100 mL of sterile BHI were
distributed in a 96-wells polypropylene tissue culture plates
(Orange Scientific1, Braine-l’Alleud, Belgium) (with flat-bot-
tom) followed by placement of 100 mL of DC in concentrations
that were prepared using a procedure similar to the one used
in the antimicrobial activity tests (MIC) with same initial
bacterial cells concentration. All the plates were incubated at
37 8C, CO2 10%, during 24 h for biofilm development. After
biofilm growth in the presence or absence of CD concentra-
tions, the content of each well was removed and the biofilms
were washed twice with 200 mL of sterilized water, to remove
cells weakly adhered.The attached biofilm mass was quantified using crystal
violet staining.35 Briefly, the plates containing the biofilms
were left to air dry for 30 min, and 200 mL of a solution sodium
acetate/formalin 2% were distributed in each well, in order to
fix the adhered cells, and left for 15 min. After this time, the
solution sodium acetate/formalin 2% was removed and 200 mL
of crystal violet 1% (Gram colour-staining set for microscopy –
Merck#) were added to each well for 5 min. Following the
staining step, the washing procedure, with sterile water, was
repeated and the plates were left at room temperature for 1 h.
To re-solubilize the dye bounded to biofilms, 200 mL of 95%
ethylic alcohol (Merck#) were added to each well and
submitted to agitation for 15 min. The crystal violet (CV)
solutions obtained were transferred to a new sterile flat
bottom 96-wells plate and the optical density of the content
was measured using a microtiter plate spectrophotometer
(Biotrak II Plate Reader – Amersham Biosciences#) at 570 nm.
2.5. CFU count
The biofilms were generated as described above and after 24 h
of incubation at 37 8C, CO2 10%, the plates were washed twice
using sterile distilled water to remove cells weakly adhered.
Then, 200 mL phosphate buffered saline pH 7.2 was added to
each well and placed in an ultrasound bath (Sonicor/SC-52#)
with 45 Hz for 10 min to release the biofilm-forming cells. A
volume of five wells (1 mL) was removed with up-down
movement, and collected in a sterile microtube. Then, 20 ml of
this cell suspension were serially diluted 10-fold for subse-
quent platting in Petri dishes with BHI agar medium. The Petri
dishes with BHI agar medium were incubated at 37 8C, CO2 10%
for 24 h. The cells were counted and the result multiplied by
the dilution factor and expressed as CFU/mL.
2.6. Statistical analysis
Statistical analyses were performed through GraphPad Prism#
version 3.00 for Microsoft Windows#. The method used was
one-way ANOVA with Bonferroni post-hoc test. The data were
obtained in thirty replicates from three separate experiments.
The graphics were presented as mean  standard deviations.
The data were considered significant when p < 0.01 or
p < 0.001.
3. Results
Initial tests to detect CD action over oral Streptococcus species
were made by disc diffusion method (Data not show) and MIC
were also determined by microdilution in 96-wells polystyrene
plates.
The MIC values for CD are shown in Table 1. Amongst
tested bacteria, CD displayed better activity against Streptococ-
cus oralis (62.5 mg/mL). MIC values ranged between 125 and
500 mg/mL against other oral bacteria. In all tests performed
the MIC values did not showed statistical difference with the
positive control, chlorhexidine ( p > 0.05). The MBC value was
500 mg/mL for Streptococcus mutans, Streptococcus salivarius,
Streptococcus sobrinus, Streptococcus mitis, Streptococcus sanguinis
and 125 mg/mL for Streptococcus oralis.
Table 1 – Minimal inhibitory concentration (MIC) of
Casbane Diterpene (CD) at different times of growth (12,
18 and 24 h) and minimal bactericidal concentration
(MBC) against oral pathogens.
Bacteria MIC (mg/mL)/time (h) MBC (mg/mL)
12 h 18 h 24 h
S. mutans 125 250 250 500
S. mitis 125 125 125 500
S. sobrinus 250 500 500 500
S. oralis 62.5 62.5 62.5 125
S. salivarius 250 250 250 500
S. sanguinis 125 250 250 500
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assessed, biomass was quantified; it was observed inhibitory
activity at 250 mg/mL concentration. Analysis of these data
showed no statistical difference ( p > 0.05) between CD and
chlorexidine control (used at 250 mg/mL) with comparisons at
all concentrations tested of CD (Fig. 2).
4. Discussion
The use of disc diffusion methodology can lead to an irregular
distribution of hydrophobic components resulting in unequal
concentrations at the agar, causing the formation of regions
with antimicrobial activity variation.36,37 On the other hand,
microdilution tests showed interesting and promising antimi-
crobial activity. The results obtained by each of these methods
may differ due to variations between the tests.37
It is known that the regular use of oral care products
containing chlorhexidine are often associated with tooth and
restoration staining, changes in the taste of food, and a burning
sensation at the tongue tip.20,38,39 This way, the search for
products with similar or better efficiency as chlorhexidine is
interesting to be introduced in dentistry clinic. Chlorhexidine
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Fig. 2 – Barr graph of biomass quantification of S. mutans
ATCC UA 159 biofilm submitted to Casbane Diterpene
(CD).*p < 0.01 related to control (normal growth).and biofilm tests, which represents a lower value when
compared to chlorhexidine concentration used in clinical
procedures, 1.200 mg/mL (0.12%). This study could show that
DC has an antimicrobial efficiency against the streptococcal
species tested similar to chlorhexidine, this way, the possible
use of DC instead of chlorhexidine depends of future toxicity
and tolerance tests. Its use could substitute chlorhexidine in
long time therapy when chlorhexidine side effects may be
detected.
The values of MBC found showed that CD has an unspecific
action against the bacteria tested. For S. mutans, MBC value
was 500 mg/mL, this way, for experiments of biofilm develop-
ment it was used the concentration of 250 mg/mL in order to
inhibit and not completely eradicate the community. The
absorbance readings were made with different times and it
was observed that at 12 hours of exposition to the compound
CD for S. mutans, S. sobrinus and S. sanguinis, the MIC value was
lower compared to the other times of exposition analysed; this
can indicate new therapeutic models for future experiments
testing CD for minutes or a few hours.
Bacteria are able to grow adhered to almost every surface,
forming architecturally complex communities termed bio-
films.40 Biofilms confer resistance to many antimicrobials and
protection against host defenses.41 Tests to check CD action
against biofilms were performed only with S. mutans; this
pathogen is considered one of the main cariogenic micro-
organisms, which is responsible for acid production leading to
carious lesion.42
At biofilm analysis no difference was found between CD
group and chlorexidine group (Fig. 2). The presence of biomass
in the control of chlorhexidine is caused by turbidity of the
substance. This is confirmed by the experiment of CFU counting
(Colonies Forming Units), in which there is absence of viable
cells when the biofilm was subjected to chlorhexidine. In CFUs
assays were observed also a considerable decrease in viable
cells number when bacterial biofilm was subjected to CD 250 mg/
mL; this confirms its inhibitory effect. The efficiency of the
inhibitory effect on biofilm development is appreciable,
considering the well known resistance of these communities.
This resistance is related to the presence of an extracellular
matrix that protects microbial cells from external aggressions.
CD decreased 94.28% on the development of biofilm within 24 h
compared to biofilm normal growth. Extracellular matrices also
act as a diffusion barrier to small molecules.41
The antimicrobial activity demonstrated by CD can be
explained by the presence of a hydrophobic moiety, and a
hydrophilic region possessing two hydrogen-bond-donor
groups. These two structural requirements may be responsi-
ble for an optimal insertion of this compound into cell
membranes through a non-specific interaction with mem-
brane phospholipids, destabilizing the non-covalent interac-
tions between the fatty acids of the lipidic bilayer, and thus
interfering on the cellular development. In addition, the effect
on biofilm formation seems to be directly related to the growth
inhibition, showing non-specific action related to the anti-
biofilm activity.22,30
Oral biofilm are one of the factors that contribute to caries
development. Natural substances that can optimize the
biofilm reduction or eradication could act as adjuvant in
therapy for patients with high risk to tooth decay. Casbane
a r c h i v e s o f o r a l b i o l o g y 5 7 ( 2 0 1 2 ) 5 5 0 – 5 5 5554Diterpene showed, for the first time, antimicrobial effect on
planktonic forms and biofilm of oral pathogens. These results
are very important, because very few natural products are
known to inhibit the growth of oral pathogens, some of which
(including Streptococcus) are responsible for dental plaque.36 So
this natural compound can be considered as a promising
molecule with potential for treatment against oral pathogens
responsible for dental plaque. Additional toxicological studies
need to be performed to validate its applicability.
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